• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Keros Therapeutics, Inc. - common stock (NQ:KROS)

11.35 +0.17 (+1.52%)
Delayed Quote Updated: 4:00 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 115,513
Open 11.15
Bid (Size) 11.18 (2,200)
Ask (Size) 12.65 (200)
Prev. Close 11.18
Today's Range 11.15 - 11.44
52wk Range 9.690 - 22.55
Shares Outstanding 23,337,862
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage ↗
Today 19:04 EDT
Keros Therapeutics (NASDAQ:KROS) is repositioning its pipeline around rinvatercept, a skeletal-muscle regeneration candidate being developed for neuromuscular diseases, while its partnered program... 
Via MarketBeat
KEROS THERAPEUTICS INC (NASDAQ:KROS) Posts Q4 2025 Earnings and Revenue Miss, Shares Decline ↗
March 04, 2026
Via Chartmill

Performance

52-Week Range 49.7% below 52-week high
11.35
9.6952W Low 22.5552W High
1 Week 2.8% below 1-week high
10.631W Low 11.681W High

Keros Therapeutics, Inc. - common stock (KROS) traded between $9.69 and $22.55 over the past 52 weeks and last traded at $11.35, 49.7% below its 52-week high. Over the past week it ranged between $10.63 and $11.68.

Past 12 Months
+6.5%
-3.2%
+11.9%
-1.8%
-38.8%
-27.1%
1W +$0.69
1M -$0.38
3M +$1.21
6M -$0.21
YTD -$7.19
1Y -$4.21

KROS was -27.1% over the past year, -1.8% over six months, -38.8% year to date, +6.5% in the last week.

12 Months vs Market
KROS
-27.1%
DIA
+13.3%
SPY
+14.4%
QQQ
+16.3%
IWM
+13.7%

Over the past 12 months KROS returned -27.1% versus DIA (Dow) +13.3%, SPY (S&P 500) +14.4%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.61× 3-mo avg
Today 115,513 3-mo avg 189.5K
1W
165.5K
1M
177.5K
3M
189.5K
6M
244.2K
YTD
304.8K
1Y
437.8K

KROS most recently traded 115,513 shares against a 3-month average daily volume of 189.5K.

More News

Read More
News headline image
Keros Therapeutics Inc (NASDAQ:KROS) Emerges as a High-Growth Momentum Breakout Candidate ↗
December 25, 2025
Via Chartmill
News headline image
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst ↗
June 10, 2025
Via Benzinga
News headline image
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% ↗
May 29, 2025
Via Benzinga
News headline image
Analyst Expectations For Keros Therapeutics's Future ↗
February 27, 2025
Via Benzinga
News headline image
Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings) ↗
January 17, 2025
Via Benzinga
News headline image
Where Keros Therapeutics Stands With Analysts ↗
December 16, 2024
Via Benzinga
News headline image
Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price ↗
April 11, 2025
Via Benzinga
News headline image
Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan ↗
April 10, 2025
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
April 10, 2025
Via Chartmill
News headline image
Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed ↗
April 10, 2025
Via Stocktwits
News headline image
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump ↗
April 10, 2025
Via Benzinga
News headline image
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday ↗
April 10, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
April 10, 2025
Via Benzinga
News headline image
Forecasting The Future: 7 Analyst Projections For Keros Therapeutics ↗
April 01, 2025
Via Benzinga
News headline image
KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the Firm
January 24, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS)
January 22, 2025
From Kirby McInerney LLP
Via Business Wire
News headline image
Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views ↗
January 15, 2025
Via Benzinga
News headline image
Nasdaq Surges Over 2%; Goldman Sachs Posts Upbeat Q4 Results ↗
January 15, 2025
Via Benzinga
News headline image
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes ↗
January 15, 2025
Via Stocktwits
News headline image
Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROS
December 17, 2024
Via ACCESSWIRE
News headline image
Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS
December 16, 2024
Via ACCESSWIRE
News headline image
Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud
December 16, 2024
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
December 12, 2024
Via Benzinga

Frequently Asked Questions

Is Keros Therapeutics, Inc. - common stock publicly traded?
Yes, Keros Therapeutics, Inc. - common stock is publicly traded.
What exchange does Keros Therapeutics, Inc. - common stock trade on?
Keros Therapeutics, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Keros Therapeutics, Inc. - common stock?
The ticker symbol for Keros Therapeutics, Inc. - common stock is KROS on the Nasdaq Stock Market
What is the current price of Keros Therapeutics, Inc. - common stock?
The current price of Keros Therapeutics, Inc. - common stock is 11.35
When was Keros Therapeutics, Inc. - common stock last traded?
The last trade of Keros Therapeutics, Inc. - common stock was at 10/22/26 04:00 PM ET
What is the market capitalization of Keros Therapeutics, Inc. - common stock?
The market capitalization of Keros Therapeutics, Inc. - common stock is 264.88M
How many shares of Keros Therapeutics, Inc. - common stock are outstanding?
Keros Therapeutics, Inc. - common stock has 265M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap